Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EMB-06 |
Synonyms | |
Therapy Description |
EMB-06 is a bispecific antibody that targets B-cell maturation antigen (BCMA) expressed on tumor cells and CD3 on T-cells, potentially leading to activation of cytotoxic T-lymphocytes (CTL) and CTL-dependent killing of tumor cells expressing BCMA, and antitumor activity (NCI Drug Dictionary, Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EMB-06 | EMB06|EMB 06 | CD3 Antibody 99 TNFRSF17 Antibody 20 | EMB-06 is a bispecific antibody that targets B-cell maturation antigen (BCMA) expressed on tumor cells and CD3 on T-cells, potentially leading to activation of cytotoxic T-lymphocytes (CTL) and CTL-dependent killing of tumor cells expressing BCMA, and antitumor activity (NCI Drug Dictionary, Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04735575 | Phase Ib/II | EMB-06 | A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma | Recruiting | AUS | 1 |